니볼루맙 치료 도중 발생한 폐포자충 폐렴 1예
Pneumocystis Pneumonia Developing during Treatment of Recurrent Renal Cell Cancer with Nivolumab
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Nivolumab is an immune checkpoint inhibitor approved for the treatment of metastatic cancers. Here, we report the case of a 65-year-old male with recurrent renal cell carcinoma. After six cycles of nivolumab treatment, positron emission tomography/ computed tomography (PET/CT) was performed to evaluate the response. PET/CT revealed diffuse ground glass opacities in both lungs. He developed a cough, sputum, chills, and a febrile sense. After bronchoscopic bronchoalveolar lavage, pneumocystis pneumonia was finally diagnosed.
Abstract
Nivolumab is an immune checkpoint inhibitor approved for the treatment of metastatic cancers. Here, we report the case of a 65-year-old male with recurrent renal cell carcinoma. After six cycles of nivolumab treatment, positron emission tomography/ computed tomography (PET/CT) was performed to evaluate the response. PET/CT revealed diffuse ground glass opacities in both lungs. He developed a cough, sputum, chills, and a febrile sense. After bronchoscopic bronchoalveolar lavage, pneumocystis pneumonia was finally diagnosed.
참고문헌 (10)
- Okazaki T, "A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application", Nat Immunol, 14, pp.1212~1218 (2013)
- Nishino M, "Incidence of programmed cell death 1 inhibitor- related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis", JAMA Oncol, 2, pp.1607~1616 (2016)
- Naidoo, "Pneumonitis in patients treated with anti-programmed death-1", programmed death ligand 1 therapy, 2017, pp.35, 709~717
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Robert C, "Nivolumab in previously untreated melanoma without BRAF mutation", N Engl J Med, 372, pp.320~330 (2015)
- Nishino M, "Anti-PD-1-related pneumonitis during cancer immunotherapy", N Engl J Med, 373, pp.288~290 (2015)
- Chiou VL, "Pseudoprogression and immune-related response in solid tumors", J Clin Oncol, 33, pp.3541~3543 (2015)
- Thomas CF Jr, "Pneumocystis pneumonia", N Engl J Med, 350, pp.2487~2498 (2004)
- Rizvi NA, "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial", Lancet Oncol, 16, pp.257~265 (2015)
- Mühlethaler K, "Quantitative PCR to diagnose pneumocystis pneumonia in immunocompromised non-HIV patients", Eur Respir J, 39, pp.971~978 (2012)